330 related articles for article (PubMed ID: 33288568)
41. Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma.
Zhou J; Huang Z; Wang Z; Liu S; Grandien A; Ernberg I; He Z; Zhang X
Oncotarget; 2017 Jul; 8(27):43853-43865. PubMed ID: 28029652
[TBL] [Abstract][Full Text] [Related]
42. The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth.
Nozawa F; Itami A; Saruc M; Kim M; Standop J; Picha KS; Cowan KH; Pour PM
Pancreas; 2004 Jul; 29(1):45-52. PubMed ID: 15211111
[TBL] [Abstract][Full Text] [Related]
43. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
Ivanov VN; Zhou H; Partridge MA; Hei TK
Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
[TBL] [Abstract][Full Text] [Related]
45. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
46. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.
Oya M; Ohtsubo M; Takayanagi A; Tachibana M; Shimizu N; Murai M
Oncogene; 2001 Jun; 20(29):3888-96. PubMed ID: 11439352
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
48. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment.
Zauli G; Sancilio S; Cataldi A; Sabatini N; Bosco D; Di Pietro R
J Cell Physiol; 2005 Mar; 202(3):900-11. PubMed ID: 15389633
[TBL] [Abstract][Full Text] [Related]
49. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.
Liu PC; Lu G; Deng Y; Wang CD; Su XW; Zhou JY; Chan TM; Hu X; Poon WS
PLoS One; 2017; 12(1):e0171157. PubMed ID: 28135339
[TBL] [Abstract][Full Text] [Related]
51. Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL.
Mazzera L; Lombardi G; Abeltino M; Ricca M; Donofrio G; Giuliani N; Cantoni AM; Corradi A; Bonati A; Lunghi P
Blood; 2013 Oct; 122(15):2641-53. PubMed ID: 23974204
[TBL] [Abstract][Full Text] [Related]
52. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
53. OSMI-1 Enhances TRAIL-Induced Apoptosis through ER Stress and NF-κB Signaling in Colon Cancer Cells.
Lee SJ; Lee DE; Choi SY; Kwon OS
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681736
[TBL] [Abstract][Full Text] [Related]
54. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis.
Shankar S; Ganapathy S; Chen Q; Srivastava RK
Mol Cancer; 2008 Jan; 7():16. PubMed ID: 18226269
[TBL] [Abstract][Full Text] [Related]
55. Water extract of Cynanchi atrati Radix regulates inflammation and apoptotic cell death through suppression of IKK-mediated NF-κB signaling.
Jeon J; Park KA; Lee H; Shin S; Zhang T; Won M; Yoon HK; Choi MK; Kim HG; Son CG; Hong JH; Hur GM
J Ethnopharmacol; 2011 Sep; 137(1):626-34. PubMed ID: 21718772
[TBL] [Abstract][Full Text] [Related]
56. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo.
Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Findlay DM; Zannettino AC; Evdokiou A
J Bone Miner Res; 2011 Mar; 26(3):630-43. PubMed ID: 20818644
[TBL] [Abstract][Full Text] [Related]
57. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
58. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.
Festa M; Petrella A; Alfano S; Parente L
Int J Cancer; 2009 Jun; 124(11):2728-36. PubMed ID: 19230027
[TBL] [Abstract][Full Text] [Related]
59. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells.
Zhang JS; Herreros-Villanueva M; Koenig A; Deng Z; de Narvajas AA; Gomez TS; Meng X; Bujanda L; Ellenrieder V; Li XK; Kaufmann SH; Billadeau DD
Cell Death Dis; 2014 Mar; 5(3):e1142. PubMed ID: 24675460
[TBL] [Abstract][Full Text] [Related]
60. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
